132183-78-9
132183-78-9
Chemical Structure
Carbamazepine-d10
Synonym(s): CBZ-d10;NSC 169864-d10
- CAS No.: 132183-78-9
- Formula:C15H2D10N2O
- Molecular Weight:246.33
IUPAC Name: 5H-dibenzo[b,f]azepine-d10-5-carboxamide
InChIKey: FFGPTBGBLSHEPO-LHNTUAQVSA-N
SMILES: NC(N1C2=C([2H])C([2H])=C([2H])C([2H])=C2C([2H])=C([2H])C3=C([2H])C([2H])=C([2H])C([2H])=C31)=O
Biological Activity: Carbamazepine-d10 is the deuterium labeled Carbamazepine. Carbamazepine (CBZ), a sodium channel blocker, is an anticonvulsant agent[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carbamazepine-d10 | 99.24% | Carbamazepine-d10 is the deuterium labeled Carbamazepine. Carbamazepine (CBZ), a sodium channel blocker, is an anticonvulsant agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine (Standard) | 99.97% | Carbamazepine (Standard) is the analytical standard of Carbamazepine. This product is intended for research and analytical applications. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine-(Ph)d8 | 98.70% | Carbamazepine-(Ph)d8 (CBZ-(Ph)d8; NSC 169864-(Ph)d8) is the deuterium labeled Carbamazepine-(Ph) (HY-B0246). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine-d4 | 99.72% | Carbamazepine-d4 (CBZ-d4) is the deuterium labeled Carbamazepine (HY-B0246). Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine-d8 | Carbamazepine-d8 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent, with an IC50 of 131 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine-d2 | Carbamazepine-d2 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine-d2,15N | Carbamazepine-d2,15N is a deuterated labeled Carbamazepine-d2,15N. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbamazepine | 99.90% | Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35. [Content Brief]
